Review of the Institute of Infection and Immunity (III) – Management Response Action Plan (MRAP)

Evaluation: Institute of Infection and Immunity
Evaluation completed: 2017/18
Evaluation lead: CIHR

Recommendation Response
(Agree/Disagree)
Management Action Plan Responsibility Timeline
1. The Panel recommends that the Institute of Infection and Immunity (III) continue with its current mandate. Agree Maintain III mandate Governing Council 2018/19 (Complete)
2. The Panel recommends that III continue to lead on emerging threats, Anti-Microbial Resistance (AMR), and HIV/AIDS initiatives. Agree III to continue to be the lead institute on emerging threats, AMR, and HIV/AIDS and maintain each as strategic research priorities Scientific Director, Institute of infection and Immunity in collaboration with the Vice-President, Research, Programs 2018/19 (Complete)
3. The Panel recommends hiring an Assistant Director, whose area of expertise complements that of the next SD. Agree Assistant Director with complementary skills to the Scientific Director will be hired Scientific Director, Institute of infection and Immunity 2018/19 (Complete)
4. The Panel recommends that the next Scientific Director have the opportunity to select some of the members of the new Institute Advisory Board. Agree Consistent with regular practice, III’s new SD will select new members of IAB (with approval by Governing Council) Scientific Director, Institute of infection and Immunity
Governing Council to approve.
2018/19 (Complete)
5. The Panel recommends the next Scientific Director target communication and outreach activities to mid-career investigators to raise awareness of III’s role and funding mechanisms, and facilitate discussion around creating innovative funding structures. Agree Develop communication strategy to highlight III’s role and methods of support (including support for mid-career investigators) Scientific Director, Institute of infection and Immunity in collaboration with the Executive Vice-President, Governance and External Relations and Vice-President, Research Programs 2018/19
6. The Panel recommends that the next Scientific Director, as part of the strategic planning process, assess previous funding opportunities to identify, prioritize, and target future funding opportunities. Agree Assessment of previous funding to be incorporated into planning process during development of new strategic plan Scientific Director, Institute of infection and Immunity in collaboration with the Vice-President, Research, Programs 2019/20
Date modified: